Fennec Pharmaceuticals (FRX) Competitors

C$13.88 +0.19 (+1.39%)

As of 03:59 PM Eastern

FRX vs. CARA, CRON, TLRY, ITH, and TEV

Should you buy Fennec Pharmaceuticals stock or one of its competitors? MarketBeat compares Fennec Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Fennec Pharmaceuticals include Cara Operations (CARA), Cronos Group (CRON), Tilray Brands (TLRY), International Tower Hill Mines (ITH), and Tervita (TEV). These companies are all part of the "pharmaceutical products" industry.

How does Fennec Pharmaceuticals compare to Cara Operations?

Fennec Pharmaceuticals (TSE:FRX) and Cara Operations (TSE:CARA) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings, media sentiment and valuation.

Given Cara Operations' higher possible upside, analysts clearly believe Cara Operations is more favorable than Fennec Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fennec Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00
Cara Operations	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

12.4% of Fennec Pharmaceuticals shares are held by institutional investors. 16.2% of Fennec Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Cara Operations has a net margin of 0.00% compared to Fennec Pharmaceuticals' net margin of -17.22%. Cara Operations' return on equity of 0.00% beat Fennec Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fennec Pharmaceuticals	-17.22%	-58.09%	8.88%
Cara Operations	N/A	N/A	N/A

In the previous week, Fennec Pharmaceuticals had 10 more articles in the media than Cara Operations. MarketBeat recorded 11 mentions for Fennec Pharmaceuticals and 1 mentions for Cara Operations. Cara Operations' average media sentiment score of 0.00 beat Fennec Pharmaceuticals' score of -0.43 indicating that Cara Operations is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fennec Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cara Operations	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cara Operations has lower revenue, but higher earnings than Fennec Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fennec Pharmaceuticals	C$51.00M	9.45	-C$800.44K	-C$0.29	N/A
Cara Operations	N/A	N/A	N/A	N/A	N/A

Summary

Fennec Pharmaceuticals beats Cara Operations on 7 of the 11 factors compared between the two stocks.

How does Fennec Pharmaceuticals compare to Cronos Group?

Fennec Pharmaceuticals (TSE:FRX) and Cronos Group (TSE:CRON) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Fennec Pharmaceuticals has a beta of 3.218074, indicating that its share price is 222% more volatile than the broader market. Comparatively, Cronos Group has a beta of 1.11805, indicating that its share price is 12% more volatile than the broader market.

Cronos Group has a net margin of -1.29% compared to Fennec Pharmaceuticals' net margin of -17.22%. Cronos Group's return on equity of -0.19% beat Fennec Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fennec Pharmaceuticals	-17.22%	-58.09%	8.88%
Cronos Group	-1.29%	-0.19%	-3.73%

In the previous week, Fennec Pharmaceuticals had 11 more articles in the media than Cronos Group. MarketBeat recorded 11 mentions for Fennec Pharmaceuticals and 0 mentions for Cronos Group. Cronos Group's average media sentiment score of 0.00 beat Fennec Pharmaceuticals' score of -0.43 indicating that Cronos Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Fennec Pharmaceuticals	Neutral
Cronos Group	Neutral

Fennec Pharmaceuticals has higher earnings, but lower revenue than Cronos Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fennec Pharmaceuticals	C$51.00M	9.45	-C$800.44K	-C$0.29	N/A
Cronos Group	C$159.54M	8.92	-C$32.78M	N/A	N/A

Cronos Group has a consensus price target of C$4.75, suggesting a potential upside of 24.67%. Given Cronos Group's higher probable upside, analysts plainly believe Cronos Group is more favorable than Fennec Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fennec Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00
Cronos Group	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

12.4% of Fennec Pharmaceuticals shares are held by institutional investors. Comparatively, 4.4% of Cronos Group shares are held by institutional investors. 16.2% of Fennec Pharmaceuticals shares are held by company insiders. Comparatively, 46.4% of Cronos Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Fennec Pharmaceuticals beats Cronos Group on 9 of the 16 factors compared between the two stocks.

How does Fennec Pharmaceuticals compare to Tilray Brands?

Fennec Pharmaceuticals (TSE:FRX) and Tilray Brands (TSE:TLRY) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.

Fennec Pharmaceuticals has a beta of 3.218074, indicating that its share price is 222% more volatile than the broader market. Comparatively, Tilray Brands has a beta of 3.243166, indicating that its share price is 224% more volatile than the broader market.

Fennec Pharmaceuticals has a net margin of -17.22% compared to Tilray Brands' net margin of -158.75%. Fennec Pharmaceuticals' return on equity of -58.09% beat Tilray Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fennec Pharmaceuticals	-17.22%	-58.09%	8.88%
Tilray Brands	-158.75%	-88.06%	-1.41%

In the previous week, Fennec Pharmaceuticals had 11 more articles in the media than Tilray Brands. MarketBeat recorded 11 mentions for Fennec Pharmaceuticals and 0 mentions for Tilray Brands. Tilray Brands' average media sentiment score of 0.00 beat Fennec Pharmaceuticals' score of -0.43 indicating that Tilray Brands is being referred to more favorably in the news media.

Company	Overall Sentiment
Fennec Pharmaceuticals	Neutral
Tilray Brands	Neutral

Fennec Pharmaceuticals has higher earnings, but lower revenue than Tilray Brands. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fennec Pharmaceuticals	C$51.00M	9.45	-C$800.44K	-C$0.29	N/A
Tilray Brands	C$858.28M	1.05	-C$183.24M	-C$14.63	N/A

Tilray Brands has a consensus price target of C$13.30, suggesting a potential upside of 77.33%. Given Tilray Brands' higher possible upside, analysts clearly believe Tilray Brands is more favorable than Fennec Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fennec Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00
Tilray Brands	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

12.4% of Fennec Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.1% of Tilray Brands shares are owned by institutional investors. 16.2% of Fennec Pharmaceuticals shares are owned by company insiders. Comparatively, 0.7% of Tilray Brands shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Fennec Pharmaceuticals beats Tilray Brands on 11 of the 16 factors compared between the two stocks.

How does Fennec Pharmaceuticals compare to International Tower Hill Mines?

International Tower Hill Mines (TSE:ITH) and Fennec Pharmaceuticals (TSE:FRX) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, media sentiment, institutional ownership, analyst recommendations and profitability.

International Tower Hill Mines has a net margin of 0.00% compared to Fennec Pharmaceuticals' net margin of -17.22%. International Tower Hill Mines' return on equity of -2.04% beat Fennec Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
International Tower Hill Mines	N/A	-2.04%	-3.65%
Fennec Pharmaceuticals	-17.22%	-58.09%	8.88%

In the previous week, Fennec Pharmaceuticals had 10 more articles in the media than International Tower Hill Mines. MarketBeat recorded 11 mentions for Fennec Pharmaceuticals and 1 mentions for International Tower Hill Mines. International Tower Hill Mines' average media sentiment score of 0.00 beat Fennec Pharmaceuticals' score of -0.43 indicating that International Tower Hill Mines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
International Tower Hill Mines	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Fennec Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

International Tower Hill Mines has a beta of 2.058962, meaning that its stock price is 106% more volatile than the broader market. Comparatively, Fennec Pharmaceuticals has a beta of 3.218074, meaning that its stock price is 222% more volatile than the broader market.

8.8% of International Tower Hill Mines shares are held by institutional investors. Comparatively, 12.4% of Fennec Pharmaceuticals shares are held by institutional investors. 0.5% of International Tower Hill Mines shares are held by insiders. Comparatively, 16.2% of Fennec Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Fennec Pharmaceuticals has higher revenue and earnings than International Tower Hill Mines. International Tower Hill Mines is trading at a lower price-to-earnings ratio than Fennec Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
International Tower Hill Mines	N/A	N/A	-C$2.36M	-C$0.01	N/A
Fennec Pharmaceuticals	C$51.00M	9.45	-C$800.44K	-C$0.29	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
International Tower Hill Mines	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Fennec Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00

Summary

Fennec Pharmaceuticals beats International Tower Hill Mines on 10 of the 14 factors compared between the two stocks.

How does Fennec Pharmaceuticals compare to Tervita?

Tervita (TSE:TEV) and Fennec Pharmaceuticals (TSE:FRX) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

Given Tervita's higher probable upside, research analysts clearly believe Tervita is more favorable than Fennec Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tervita	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Fennec Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00

Fennec Pharmaceuticals has lower revenue, but higher earnings than Tervita. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Tervita, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tervita	C$1.36B	0.00	-C$1.04M	-C$0.01	N/A
Fennec Pharmaceuticals	C$51.00M	9.45	-C$800.44K	-C$0.29	N/A

In the previous week, Fennec Pharmaceuticals had 11 more articles in the media than Tervita. MarketBeat recorded 11 mentions for Fennec Pharmaceuticals and 0 mentions for Tervita. Tervita's average media sentiment score of 0.00 beat Fennec Pharmaceuticals' score of -0.43 indicating that Tervita is being referred to more favorably in the media.

Company	Overall Sentiment
Tervita	Neutral
Fennec Pharmaceuticals	Neutral

Tervita has a net margin of 0.00% compared to Fennec Pharmaceuticals' net margin of -17.22%. Tervita's return on equity of 0.00% beat Fennec Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tervita	N/A	N/A	N/A
Fennec Pharmaceuticals	-17.22%	-58.09%	8.88%

Summary

Fennec Pharmaceuticals beats Tervita on 8 of the 14 factors compared between the two stocks.

Get Fennec Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FRX vs. The Competition

Export

Metric	Fennec Pharmaceuticals	Biotechnology Industry	Medical Sector	TSE Exchange
Market Cap	C$482.15M	C$477.13M	C$6.45B	C$12.16B
Dividend Yield	2.02%	3.87%	2.76%	6.20%
P/E Ratio	-47.86	3.81	17.93	37.64
Price / Sales	9.45	7,288.62	553.92	11.68
Price / Cash	11.66	13.13	43.49	82.29
Price / Book	12.68	84.78	10.37	4.50
Net Income	-C$800.44K	-C$96.07M	C$3.57B	C$299.09M
7 Day Performance	4.28%	1.01%	6.01%	1.38%
1 Month Performance	48.45%	0.50%	3.52%	1.46%
1 Year Performance	N/A	64.34%	34.13%	55.45%

Fennec Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FRX Fennec Pharmaceuticals	0.0572 of 5 stars	C$13.88 +1.4%	N/A	N/A	C$482.15M	C$51.00M	N/A	10	Analyst Revision
CARA Cara Operations	N/A	N/A	N/A	N/A	C$1.62B	N/A	N/A	80
CRON Cronos Group	2.4406 of 5 stars	C$3.61 -4.0%	C$4.75 +31.6%	+35.1%	C$1.35B	C$159.54M	N/A	450
TLRY Tilray Brands	1.2803 of 5 stars	C$7.28 -3.4%	C$13.30 +82.7%	+22.2%	C$901.95M	C$858.28M	N/A	2,650
ITH International Tower Hill Mines	N/A	C$3.39 -6.9%	N/A	+173.3%	C$886.95M	N/A	N/A	220	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:FRX) was last updated on 5/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fennec Pharmaceuticals (FRX) Competitors

FRX vs. CARA, CRON, TLRY, ITH, and TEV

How does Fennec Pharmaceuticals compare to Cara Operations?

Summary

How does Fennec Pharmaceuticals compare to Cronos Group?

Summary

How does Fennec Pharmaceuticals compare to Tilray Brands?

Summary

How does Fennec Pharmaceuticals compare to International Tower Hill Mines?

Summary

How does Fennec Pharmaceuticals compare to Tervita?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FRX vs. The Competition

Fennec Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fennec Pharmaceuticals (FRX) Competitors

FRX vs. CARA, CRON, TLRY, ITH, and TEV

How does Fennec Pharmaceuticals compare to Cara Operations?

Do analysts prefer FRX or CARA?

Do insiders and institutionals believe in FRX or CARA?

Is FRX or CARA more profitable?

Does the media refer more to FRX or CARA?

Which has preferable valuation & earnings, FRX or CARA?

Summary

How does Fennec Pharmaceuticals compare to Cronos Group?

Which has more risk and volatility, FRX or CRON?

Is FRX or CRON more profitable?

Does the media prefer FRX or CRON?

Which has preferable valuation & earnings, FRX or CRON?

Do analysts rate FRX or CRON?

Do institutionals & insiders hold more shares of FRX or CRON?

Summary

How does Fennec Pharmaceuticals compare to Tilray Brands?

Which has more volatility & risk, FRX or TLRY?

Is FRX or TLRY more profitable?

Does the media favor FRX or TLRY?

Which has better valuation & earnings, FRX or TLRY?

Do analysts prefer FRX or TLRY?

Do insiders & institutionals hold more shares of FRX or TLRY?

Summary

How does Fennec Pharmaceuticals compare to International Tower Hill Mines?

Is ITH or FRX more profitable?

Does the media refer more to ITH or FRX?

Which has more risk and volatility, ITH or FRX?

Do institutionals & insiders hold more shares of ITH or FRX?

Which has stronger valuation & earnings, ITH or FRX?

Do analysts recommend ITH or FRX?

Summary

How does Fennec Pharmaceuticals compare to Tervita?

Do analysts recommend TEV or FRX?

Which has stronger earnings & valuation, TEV or FRX?

Do insiders and institutionals believe in TEV or FRX?

Does the media prefer TEV or FRX?

Is TEV or FRX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FRX vs. The Competition

Fennec Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools